Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study
Farah Khorassani, Ricardo Azevedo, Reza Farokhpay · 2024
Read Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study by Farah Khorassani, Ricardo Azevedo, Reza Farokhpay (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616304.txt.
Description
Farah Khorassani, Ricardo Azevedo, and Reza Farokhpay give a case study that sets drug monitoring next to genetic testing, for the dose of antipsychotic drugs. Their 2024 case deals with high olanzapine levels, and with a past case in which clozapine was not borne well.
The patient was a man in his early thirties, with schizoaffective disorder. He got movement symptoms from more than one antipsychotic drug used at once. A blood test, done while he was on a raised dose of olanzapine, showed a level far above the range used for therapy. Genetic testing gave no result that could be used. The variants that count had been left out of the panel. Monitoring, in its place, guided a slow cross-taper to clozapine. That drug worked well and was borne well. The case says that monitoring can do more than genetic panels that are not full.
Catalog record
| CREATOR | Farah Khorassani, Ricardo Azevedo, Reza Farokhpay |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |